What’s more, this team proposed that acquired resistance to anti-EGFR therapy was a fait accompli and that the timing of the emergence of resistance depended on the time interval required for tumor cell subclones to repopulate the lesion (15). The gene discussed is EGFR; the disease is neoplasm.